In last trading session, Monopar Therapeutics Inc (NASDAQ:MNPR) saw 52437.0 shares changing hands with its beta currently measuring 1.22. Company’s recent per share price level of $24.46 trading at -$0.7 or -2.78% at ring of the bell on the day assigns it a market valuation of $148.63M. That closing price of MNPR’s stock is at a discount of -57.4% from its 52-week high price of $38.50 and is indicating a premium of 93.7% from its 52-week low price of $1.54. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 43990.0 shares which gives us an average trading volume of 520.80K if we extend that period to 3-months.
For Monopar Therapeutics Inc (MNPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Monopar Therapeutics Inc (NASDAQ:MNPR) trade information
Upright in the red during last session for losing -2.78%, in the last five days MNPR remained trading in the green while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $24.46 price level, adding 3.7% to its value on the day. Monopar Therapeutics Inc’s shares saw a change of 11.18% in year-to-date performance and have moved 11.18% in past 5-day. Monopar Therapeutics Inc (NASDAQ:MNPR) showed a performance of 13.77% in past 30-days. Number of shares sold short was 49852.0 shares which calculate 0.15 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 29.5 to the stock, which implies a rise of 17.08% to its current value. Analysts have been projecting 22 as a low price target for the stock while placing it at a high target of 37. It follows that stock’s current price would jump 10.06% in reaching the projected high whereas dropping to the targeted low would mean a gain of 10.06% for stock’s current value.
Monopar Therapeutics Inc (MNPR) estimates and forecasts
Statistics highlight that Monopar Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 594.89% of value to its shares in past 6 months, showing an annual growth rate of 45.90% while that of industry is 17.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -14.80% during past 5 years.
Monopar Therapeutics Inc (NASDAQ:MNPR)’s Major holders
Insiders are in possession of 42.94% of company’s total shares while institution are holding 24.47 percent of that, with stock having share float percentage of 42.89%. Investors also watch the number of corporate investors in a company very closely, which is 24.47% institutions for Monopar Therapeutics Inc that are currently holding shares of the company. MILLENNIUM MANAGEMENT LLC is the top institutional holder at MNPR for having 0.19 million shares of worth $0.15 million. And as of 2024-06-30, it was holding 1.2159 of the company’s outstanding shares.
The second largest institutional holder is GEODE CAPITAL MANAGEMENT, LLC, which was holding about 60036.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.3757 of outstanding shares, having a total worth of $44906.0.